A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer

Frigerio, Barbara; Fracasso, Giulio; Luison, Elena; Cingarlini, Sara; Mortarino, Mimosa; Coliva, Angela; Seregni, Ettore; Bombardieri, Emilio; Zuccolotto, Gaia; Rosato, Antonio; Colombatti, Marco; Canevari, Silvana; Figini, Mariangela

doi:10.1016/j.ejca.2013.01.024

Cited by 49 publications

(69 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was tried to circumvent using only fragments against the external domain of the PSMA receptor. An early preclinical study showed this potential for scFvD2B [26].…”

Section: Extracellular Psma Domain-monoclonal Antibodymentioning

confidence: 97%

Imaging for Prostate Cancer

Zechmann

2015

Curr Radiol Rep

View full text Add to dashboard Cite

We review recent developments in imaging for prostate cancer. Technical advances in magnetic resonance imaging (MRI), hybrid imaging with combined positron emission tomography (PET) and ultrasound (US) are presented. Especially in the area of tracer and contrast agent development several publications are highlighted. For detection of primary prostate cancer multiparametric MRI (mpMRI) using T2w sequences, diffusion-weighted imaging, dynamic contrast-enhanced MRI, and/or 1H-MR spectroscopy is meanwhile considered as standard. However, the lack of standardization in reporting is evident. Most differential diagnostic problems are solved. Therefore mpMRI is increasingly used for therapy planning and fusion with US/MR-guided biopsies to overcome negative conventional biopsy results. Also imaging after prior treatment is of interest to define normal effects of e.g., radiotherapy. For detection of recurrent tumor, targeting the prostate-specific membrane antigen in PET/CT has revolutionized imaging. This promising technique is paving the way for future treatment with radiolabeled agents.

show abstract

“…This was tried to circumvent using only fragments against the external domain of the PSMA receptor. An early preclinical study showed this potential for scFvD2B [26].…”

Section: Extracellular Psma Domain-monoclonal Antibodymentioning

confidence: 97%

Imaging for Prostate Cancer

Zechmann

2015

Curr Radiol Rep

View full text Add to dashboard Cite

show abstract

“…To capture PSMA antigen, our pillars have been functionalized with an antibody anti PSMA , the D2B, recently isolated by some of us (Colombatti et al 2010;Frigerio et al 2013;Tykvart et al 2014). We exploited the high binding capability of D2B which recognizes the extracellular domain of PSMA with a Kd lower than the value of the benchmark Ab J591 (Chang et al 1999).…”

Section: Psma Detection In Buffer and Serummentioning

confidence: 99%

Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection

Tardivo

Toffoli

Fracasso

et al. 2015

Biosensors and Bioelectronics

View full text Add to dashboard Cite

“…[83] The main bacterial workhorse, Escherichia coli, [81,84] has shortcomings in disulfide bridge formation and folding of complex, multimeric proteins [85] while its inability to carry out glycosylation in particular remains a bottleneck in the expression of many therapeutically relevant molecules, despite recent advances in engineering a nonnative glycosylation machinery. [86] Complex proteins of relevance to functionalization of biomaterial surfaces that have been successfully produced in E. coli to date include antibodies against tumor markers such as human epidermal growth factor receptor 2 (HER-2) [87] and prostate specific membrane antigen, [88] as well as bone morphogenic protein (BMP-2), [89] VEGF [90] and IGF1. [91] Challenging recombinant targets may also be expressed in eucaryotic species to exploit their more sophisticated folding or secretion apparatus, or to access their native post-translational modification machineries.…”

Section: Expression Systems For Recombinant Productsmentioning

confidence: 99%

Adding Functions to Biomaterial Surfaces through Protein Incorporation

et al. 2016

View full text Add to dashboard Cite

The concept of biomaterials has evolved from one of inert mechanical supports with a long-term, biologically inactive role in the body into complex matrices that exhibit selective cell binding, promote proliferation and matrix production, and may ultimately become replaced by newly generated tissues in vivo. Functionalization of material surfaces with biomolecules is critical to their ability to evade immunorecognition, interact productively with surrounding tissues and extracellular matrix, and avoid bacterial colonization. Antibody molecules and their derived fragments are commonly immobilized on materials to mediate coating with specific cell types in fields such as stent endothelialization and drug delivery. The incorporation of growth factors into biomaterials has found application in promoting and accelerating bone formation in osteogenerative and related applications. Peptides and extracellular matrix proteins can impart biomolecule- and cell-specificities to materials while antimicrobial peptides have found roles in preventing biofilm formation on devices and implants. In this progress report, we detail developments in the use of diverse proteins and peptides to modify the surfaces of hard biomaterials in vivo and in vitro. Chemical approaches to immobilizing active biomolecules are presented, as well as platform technologies for isolation or generation of natural or synthetic molecules suitable for biomaterial functionalization.

show abstract

A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer

Cited by 49 publications

References 27 publications

Imaging for Prostate Cancer

Imaging for Prostate Cancer

Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection

Adding Functions to Biomaterial Surfaces through Protein Incorporation

Contact Info

Product

Resources

About